InVivo Therapeutics Announces Appointment of Robert Rosenthal to Board of Directors
November 12 2019 - 8:00AM
Business Wire
InVivo Therapeutics Holdings Corp. (NVIV) today announced
the appointment of Robert J. Rosenthal, Ph.D., to the Company’s
Board of Directors, effective November 8, 2019. Dr. Rosenthal
brings more than 25 years of experience to the InVivo Board as an
accomplished executive and business leader in the biotechnology,
therapeutics and medical device industries. With the addition of
Dr. Rosenthal, InVivo’s Board has six members, five of whom are
independent.
“Dr. Rosenthal’s deep experience across a range of corporate
functions, from corporate development and business operations, to
strategic planning and capital market transactions, will be a
highly valuable addition to our Board as we guide the Company
forward toward its near- and long-term goals,” said Ann Merrifield,
InVivo’s Chair of the Board of Directors.
Dr. Rosenthal currently serves as Chairman of the Board of
Taconic Biosciences, Inc., a privately-held provider of research
models for the pharmaceutical and biotech industry, where from 2014
to 2018 he also served as Chief Executive Officer. Dr. Rosenthal
also currently serves as a director of the Bruker Corporation, a
publicly traded manufacturer of analytic instruments, since 2015.
Dr. Rosenthal has served since 2007 as a director of Safeguard
Scientifics, Inc., a publicly-traded provider of capital for early-
and growth-stage companies, and as Chairman of its board of
directors since May 2016. He also currently serves as a director of
Galvanic Applied Sciences, Inc., a privately-held Canadian company,
since 2013.
“I am excited to join the InVivo Board at this critical period
in the company’s history, and I look forward to working together
with the Board and the InVivo team as InVivo continues advancing
down its clinical pathway to ultimately address an area of
significant unmet need for spinal cord injury patients,” commented
Dr. Rosenthal.
Dr. Rosenthal has more than 25 years of experience in a variety
of senior management positions with companies involved in the
development of therapeutics, medical devices, diagnostics and life
sciences tools, most recently including from 2010 through 2012 as
President and Chief Executive Officer of IMI Intelligent Medical
Implants, AG, a medical technology company, and from 2005 through
2009 as President and Chief Executive Officer of Magellan
Biosciences, Inc., a provider of clinical diagnostics and life
sciences research tools. Earlier in his career, Dr. Rosenthal
served in senior management positions at Perkin Elmer Inc. and
Thermo Fisher Scientific, Inc.
Dr. Rosenthal holds a Ph.D. from Emory University and a Master
of Science degree from the State University of New York.
About InVivo Therapeutics
InVivo Therapeutics Holdings Corp. is a research and
clinical-stage biomaterials and biotechnology company with a focus
on treatment of spinal cord injuries. The company was founded in
2005 with proprietary technology co-invented by Robert Langer,
Sc.D., Professor at Massachusetts Institute of Technology, and
Joseph P. Vacanti, M.D., who then was at Boston Children’s Hospital
and who now is affiliated with Massachusetts General Hospital. The
publicly traded company is headquartered in Cambridge, MA. For more
details, visit www.invivotherapeutics.com.
Safe Harbor Statement
Any statements contained in this press release that do not
describe historical facts may constitute forward-looking statements
within the meaning of the federal securities laws. These statements
can be identified by words such as “believe,” “anticipate,”
“intend,” “estimate,” “will,” “may,” “should,” “expect” and similar
expressions, and include statements regarding the expectations
related to continued progress with and updates from InVivo’s
clinical pathway, corporate development and strategic planning. Any
forward-looking statements contained herein are based on current
expectations and are subject to a number of risks and
uncertainties. Factors that could cause actual future results to
differ materially from current expectations include, but are not
limited to, risks and uncertainties relating to the Company’s
ability to successfully open additional clinical sites for
enrollment and to enroll additional patients; the timing of the
Institutional Review Board process; the Company’s ability to obtain
FDA approval to commercialize its products; the Company’s ability
to develop, market and sell products based on its technology; the
expected benefits and efficacy of the Company’s products and
technology in connection with spinal cord injuries; the
availability of substantial additional funding for the Company to
continue its operations and to conduct research and development,
clinical studies and future product commercialization; and other
risks associated with the Company’s business, research, product
development, regulatory approval, marketing and distribution plans
and strategies identified and described in more detail in the
Company’s Quarterly Report on Form 10-Q for the quarter ended
September 30, 2019, and its other filings with the SEC, including
the Company’s Form 10-K, Form 10-Qs and current reports on Form
8-K. The Company does not undertake to update these forward-looking
statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20191112005592/en/
IR CONTACT: Bret Shapiro, Managing Partner CORE IR Phone:
(516) 222-2560 brets@coreir.com
MEDIA CONTACT: Jules Abraham CORE IR Phone: (917)
885-7378 julesa@coreir.com
InVivo Therapeutics (NASDAQ:NVIV)
Historical Stock Chart
From Mar 2024 to Apr 2024
InVivo Therapeutics (NASDAQ:NVIV)
Historical Stock Chart
From Apr 2023 to Apr 2024